Research Article Details
| Article ID: | A12038 |
| PMID: | 30630004 |
| Source: | Life Sci |
| Title: | A maternal high-fat diet may accelerate adipo-immunologic aging in offspring. |
| Abstract: | AIM: Maternal obesity and improper nutrition predispose offspring to chronic metabolic diseases. Although the frequency of these diseases increases with aging, the effect of a maternal high-fat diet on aged offspring remains elusive. MAIN METHODS: C57BL/6J female mice were fed a high-fat (HF) diet or a control (CON) diet and then mated. All offspring remained with their birth dam until weaning at 3 weeks. After weaning, the offspring from the HF and CON diet-fed dams were given either the HF diet or CON diet, which resulted in four groups: CON/CON, CON/HF, HF/CON, and HF/HF. All mice were immunized with ovalbumin and then sacrificed at 70 weeks. KEY FINDINGS: The body weights in offspring from dam exposed to a HF diet were significantly higher than those in offspring from dam fed a CON diet in the early stage of life but then became lower in the later stage of life. The serum adiponectin levels were lower in offspring from dam exposed to a HF diet and were correlated with adiposity measured by visceral and subcutaneous fat mass. Non-alcoholic fatty liver disease was much more severe in the livers of offspring from the maternal HF groups. In particular, lobular inflammation and fibrosis were prominent in the HF/HF group. Regarding immunological parameters, senescence-associated T cells were increased, and natural killer T cells were decreased by the effect of both maternal and offspring HF diet. SIGNIFICANCE: We have demonstrated that a maternal high-fat diet may accelerate the adipo-immunologic aging process. |
| DOI: | 10.1016/j.lfs.2019.01.008 |
| Strategy ID | Therapy Strategy | Synonyms | Therapy Targets | Therapy Drugs | |
|---|---|---|---|---|---|
| S03 | Anti-fibrosis | fibrosis | Angiotensin Receptor Blocker (ARB); CCR2/CCR5 antagonist; Thyroid receptor β agonist; PEGylated human FGF21 analogue; Monoclonal antibody to lysyl oxidase-like 2 (LOXL2); Galectin-3 inhibitor; FGF19 variant | Losartan; Cenicriviroc; VK-2809; MGL-3196; Pegbelfermin; Simtuzumab; GR-MD-02; NGM282 | Details |
| Diseases ID | DO ID | Disease Name | Definition | Class | |
|---|---|---|---|---|---|
| I14 | 9970 | Obesity | An overnutrition that is characterized by excess body fat, traditionally defined as an elevated ratio of weight to height (specifically 30 kilograms per meter squared), has_material_basis_in a multifactorial etiology related to excess nutrition intake, decreased caloric utilization, and genetic susceptibility, and possibly medications and certain disorders of metabolism, endocrine function, and mental illness. https://en.wikipedia.org/wiki/Obesity | disease of metabolism/acquired metabolic disease/ nutrition disease/overnutrition | Details |
| Drug ID | Drug Name | Type | DrugBank ID | Targets | Category | Latest Progress | |
|---|---|---|---|---|---|---|---|
| D328 | Serine | Chemical drug | DB00133 | SRR | Improve insulin resistance | Under clinical trials | Details |
| D579 | Emfilermin | Miscellany | -- | adipocytes | Enhance lipid metabolism | Under investigation | Details |
| D094 | Cysteamine | Chemical drug | DB00847 | GSS stimulant | Renal drug | Under clinical trials | Details |
| D095 | Cysteamine bitartrate | Chemical drug | DB00847 | -- | -- | Under clinical trials | Details |